Tonix Q2 2026: TONMYA Sales Triple to $11M, Cash Runway into Q2 2027

summarizeSummary

Tonix Pharmaceuticals reported Q2 2026 results with TONMYA net sales of $11 million, a 197% sequential increase, and $176.2 million in cash providing runway into early Q2 2027. The company also advanced key pipeline programs and expanded its sales force.

check_boxKey Events · Earnings and Guidance · TNXP

• TONMYA Sales Surge

  Net sales of TONMYA reached $11.0 million in Q2 2026, up 197% from Q1, driven by 100% prescription growth and expanding payer coverage now at ~136 million lives.

• Cash Runway Extended

  Cash and equivalents of $176.2 million as of June 30, 2026, plus $3.7 million raised via ATM post-quarter, are expected to fund operations into early Q2 2027.

• Pipeline Milestones

  First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for major depressive disorder; Phase 2 Lyme prevention study for TNX-4800 on track for Q1 2027 start.

• Commercial Expansion

  Sales force expanding to approximately 150 representatives by September 2026 to support TONMYA uptake; managed Medicare coverage adding ~9 million lives effective January 1, 2027.

auto_awesomeAnalysis · TNXP · Life Sciences

A strong commercial ramp for fibromyalgia drug TONMYA drove net sales to nearly triple quarter-over-quarter, reaching $11 million. With $176.2 million in cash at quarter-end, the company expects funding into early Q2 2027—a critical update given the ongoing going-concern warning. Pipeline progress includes enrolling the first patient in a pivotal Phase 2 depression study and securing FDA alignment on a Lyme disease prevention trial. Confidence in continued uptake is underscored by the sales force expanding to 150 reps by September. Still, the net loss widened to $40.6 million, and an additional $3.7 million was raised via the ATM after the quarter, highlighting ongoing cash needs.